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Abstract
Background: Glioblastomas (GBM) continue to remain one of the most dreaded tumours that are highly infiltrative in
nature and easily preclude comprehensive surgical resection. GBMs pose an intricate etiology as they are being associated
with a plethora of genetic and epigenetic lesions. Misregulation of the PI3 kinase pathway is one of the most familiar
events in GBM. While the PI3 kinase signalling regulated pathways and genes have been comprehensively studied, its
impact on the miRNome is yet to be explored. The objective of this study was to elucidate the PI3 kinase pathway
regulated miRNAs in GBM.
Methods: miRNA expression profiling was conducted to monitor the differentially regulated miRNAs upon PI3 kinase
pathway abrogation. qRT-PCR was used to measure the abundance of miR-326 and its host gene encoded transcript.
Proliferation assay, colony suppression assay and wound healing assay were carried out in pre-miR transfected cells to
investigate its role in malignant transformation. Potential targets of miR-326 were identified by transcriptome analysis of
miR-326 overexpressing cells by whole RNA sequencing and selected targets were validated. Several publically available
data sets were used for various investigations described above.
Results: We identified several miRNA that were regulated by PI3 kinase pathway. miR-326, a GBM downregulated miRNA,
was validated as one of the miRNAs whose expression was alleviated upon abrogation of the PI3 kinase pathway.
Overexpression of miR-326 resulted in reduced proliferation, colony suppression and hindered the migration capacity of
glioma cells. Arrestin, Beta 1 (ARRB1), the host gene of miR-326, was also downregulated in GBM and interestingly, the
expression of ARRB1 was also alleviated upon inhibition of the PI3 kinase pathway, indicating similar regulation pattern.
More importantly, miR-326 exhibited a significant positive correlation with ARRB1 in terms of its expression. Transcriptome
analysis upon miR-326 overexpression coupled with integrative bioinformatics approach identified several putative targets
of miR-326. Selected targets were validated and interestingly found to be upregulated in GBM.
Conclusions: Taken together, our study uncovered the PI3 kinase regulated miRNome in GBM. miR-326, a PI3 kinase
pathway inhibited miRNA, was demonstrated as a tumour suppressor miRNA in GBM.
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Background
The last decade has seen an emergence of microRNAs
(miRNAs) as the paramount biomolecules which have
carved a substantial niche in almost every physiological
process. A number of studies have elucidated the role of
miRNAs in a wide variety of regulatory pathways which
control development, differentiation, apoptosis, cell pro-
liferation and organogenesis [1, 2]. miRNAs are a class
of short, single stranded RNA molecules which do not
encode for any protein, rather they modulate the expres-
sion of a myriad of proteins in a cell by fine-tuning their
transcript levels. miRNAs function as guide molecules
and bind to their targets with near perfect complemen-
tarity and bring about their translational repression or
transcript degradation. miRNAs are synthesized from an
endogenous transcript that bears a local hairpin struc-
ture, which after multiple steps of processing culminates
into a 19–25 nucleotide long mature functional miRNA
[3, 4]. miRNAs account for ~1 % of the genome thereby
constitute one of the largest gene families [5].
miRNA biology has added an intricate complicacy in the
arena of gene regulation, owing to its versatile modes of
regulation. It is highly likely for a miRNA to target more
than one mRNA, and similarly for one mRNA to be tar-
geted by several miRNAs. Being epigenetic regulators of
gene expression, miRNAs bring about subtle, but equally
crucial changes in the expression landscape of a cell and
thereby alter its phenotype. The past decade has seen a tre-
mendous surge in the amount of literature highlighting the
importance of miRNAs in malignant transformation. The
aberrant expression of miRNAs has a detrimental effect on
the development and progression of human cancers [6, 7].
On similar grounds, miRNAs can be categorized either as
oncogenic miRNAs or tumour suppressor miRNAs de-
pending upon their function and expression in a malig-
nant scenario. Thus a malignant phenotype can easily
be conceived to be a consequence of the misregulation
of these small non-coding RNAs in a close nexus with
multiple other oncogenic factors and pathways.
Astrocytomas are the most common neoplasms of the
central nervous system accounting for about 60 % of the
primary brain tumours in humans [8]. Glioblastoma which
is a grade IV astrocytoma represents the most lethal form
of intracranial tumour. The radical resection of the primary
tumour mass is not curative, as glioblastomas are highly
invasive and diffusely infiltrate throughout the brain. The
remnant neoplastic mass which inevitably stays back after
surgery, potentially leads to tumour recurrence and
mortality. Glioblastomas inexorably portend grave clin-
ical outcome and dismal prognosis, thereby rendering
them the most belligerent and aggressive intracranial
tumours. The current standard of care for glioblastoma
management involves maximal near safe surgical resection
of the tumour, followed by an aggressive adjuvant radiation
therapy and chemotherapy with the oral alkylating agent
temozolomide. Despite the advances in the current
treatment regimens that are leveraged to manage GBM,
it eludes efficient treatment as its prognosis continues
to remain poor with the median survival of the patients
lying at a dismal 12–15 months [9, 10]. This necessitates us
to look into the intricacies of this malignancy and elucidate
the novel driver events which might play an instrumental
role in the initiation and progression of glioblastoma. In the
wake of same, TCGA network made a concerted effort to
comprehend GBM better and examined the different clas-
ses of events in GBM, like mutational, copy number alter-
ations which affect the expression and activity of important
pathways [11]. TCGA integrated large-scale multi-platform
data and revealed three core pathways: p53, pRb and RTK
pathways, which most often get derailed in glioblastoma.
p53 is a well-known tumour suppressor as it foils the prolif-
eration of cells with damaged genome, by halting the cell
cycle in the G1 phase or bringing about apoptosis [12]. The
p53 signalling is found to be altered in 87 % of the GBM
cases owing to the deletion or mutations in p53, CDKN2A
and amplifications of MDM2 and MDM4 [11]. Similarly
the pRB pathway, which also arrests the growth of cells by
sequestering the E2F family of transcription factors, is
found to be misregulated in 78 % of samples [11]. The third
core pathway that is derailed in GBM is the Receptor
Tyrosine Kinase (RTK) signalling, which is disrupted in
88 % of the GBM cases [11]. One of the key downstream
signalling channels of the RTK pathway, through which
the different RTKs likes EGFR, ERBB2, PDGF and MET
transduce their signalling is the phosphoinositide 3-kinase
(PI3K) pathway. About 15 % of the GBM samples exhibit
mutations in PI3K. Moreover PTEN (phosphatase and
tensin homolog), an enzyme which antagonizes the activity
of PI3K, suffers from mutation and homozygous deletion
in 36 % of GBM cases [11].
PI3 kinase pathway, which is a branch of the RTK
signalling, is a pro-proliferative pathway and is drastically
altered in GBM [11]. The members of the PI3 kinase path-
way play a decisive role in the malignant transformation of
a cell. They are actively involved in the regulation of prolif-
eration, differentiation, migration, trafficking, and glucose
homeostasis [13]. Aberrant signalling through PI3 kinase
pathway results in the alteration of expression of a vast
array of proteins including transcription factors which
eventually mutilate the normal expression landscape of the
cell. Activation of the PI3 kinase pathway is a recurrent fea-
ture observed in human tumours [14]. As the growth factor
ligands bind to the membrane receptor tyrosine kinases
leading to their dimerization and autophosphorylation, they
trigger the activation of PI3 kinase which through their
catalytic activity convert phosphatidylinositol (3,4)-bis-
phosphate (PIP2) lipids to phosphatidylinositol (3,4,5)-
tris-phosphate (PIP3) [15]. PKB/Akt binds with high
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affinity to PIP3 which leads to its mobilization to the
plasma membrane, where it is subsequently phosphorylated
on the T308 residue in its activation loop by PDK1, leading
to its partial activation [16]. Complete activation is achieved
through the phosphorylation of S473, which could be
catalysed by various proteins, including phosphoinosi-
tide-dependent kinase 2 (PDK2), integrin-linked kinase
(ILK), mTOR and DNA-dependent protein kinase
(DNA-PK) [17, 18]. Phosphorylated Akt triggers down-
stream pathways that regulate and support cellular growth
and survival by various mechanisms, including the phos-
phorylation and activation of mTOR kinase, transcription
factor NFkB, and MDM2 E3 ubiquitin ligase, as well as
the inactivation of pro-apoptotic protein BAD and FOXO1
transcription factor, thereby aiding malignant transform-
ation [15, 19]. In addition to the protein coding genes, the
oncogenic behaviour of the PI3K pathway could also be
attributed and extended to the deregulation of miRNAs
due to its aberrant activity in the malignant state. This set
of miRNAs could possibly represent a cohort of miRNAs
whose levels are altered by the PI3 kinase signalling, which
otherwise in untransformed astrocytes regulate and fine-
tune the levels of various oncogenes including RTKs.
In the current study, we identified a cohort of miRNAs
that are regulated by PI3 kinase signalling. We further
shortlisted and validated miR-326, an intragenic miRNA, as
a downregulated miRNA in GBM, whose levels are brought
down by PI3 kinase activity. Additionally, we also observed
that the host gene of miR-326, ARRB1 is also subjected to
similar regulation by the PI3 kinase signalling.
Methods
Human tumour samples
In this study, the glioblastoma tissue samples that were
used were obtained from the patients who were operated
in Sri Sathya Sai Institute of Higher Medical Sciences
(SSSIHMS) and National Institute of Mental Health and
Neurosciences (NIMHANS), Bangalore, India. We used
non-tumour brain which comprised of anterior temporal
lobe of the brain for the purpose of comparison. The
non-tumour brain was obtained during the surgery of
intractable epilepsy patients. The tissues both tumour
and non-tumour control were snap-frozen in liquid
nitrogen and stored at −80 °C and used for RNA isola-
tion. A total of 56 GBM samples and 14 control brain
samples were used in this study. The different experimental
protocols methods and adopted in this study strictly follow
the guidelines approved by the Institutional biosafety clear-
ance committee of Indian Institute of Science, Bangalore.
Cell culture
Glioma cell lines U87, U138, U251, U343, U373, LN229,
LN18 and T98G were grown in Dulbecco’s Modified Eagle’s
medium (DMEM, Sigma) while SVG cells were grown in
MEM. The medium was supplemented with 10 % foetal
bovine serum (FBS, Gibco, ThermoFisher) along with
penicillin and streptomycin. The cells were maintained
in in a humidified incubator at 37 °C and 5 % CO2.
Most of the used cell lines were procured from ECACC
(European Collection of Authenticated Cell Cultures).
Immortalized human astrocytes (IHA) were a kind gift
from late Dr. Abhijit Guha.
RNA extraction, cDNA conversion and quantitative RT-PCR
analysis
Total cellular RNA including the miRNA fraction was
isolated using Trizol reagent (sigma). RNA thus isolated
was analysed for its purity and integrity by Nano-drop
and gel electrophoresis. Two μg of total RNA were used
for cDNA conversion using High capacity cDNA reverse
transcription kit the (Applied Biosystems, USA) according
to the manufacturer’s protocol. cDNA generated was
diluted with nuclease free water in the ratio of 1: 10
such that the final concentration of the cDNA was 10 ng/μl.
Real-time PCR was done using the ABI PRISM 7900 HT
Sequence Detection System (Life technologies, USA) under
default conditions: 95 °C for 15 min, 40 cycles of 95 °C for
15 s, 60 °C for 20 s and 72 °C for 25 s. Expression was ana-
lyzed using GAPDH, 18S RNA and RPL35a as a reference
gene and the ddCt method [20].
Real-Time qPCR for quantification of miRNAs
For the detection and estimation of miRNAs, we
employed a TaqMan based real-time PCR method
(Applied Biosystems). The TaqMan real-time PCR method
involves the formation of miRNA-specific cDNA from total
RNA (10 ng) using a specific stem-loop primer. A diluted
reverse transcription product, which is a miRNA specific
cDNA was used for each real-time PCR reaction. Real-time
PCR was performed using the ABI PRISM 7900 HT
Sequence Detection System (Life technologies, USA). The
thermal profile of the PCR was as follows: 95 °C for 10 min
and then 40 cycles of 95 °C for 15 s and 60 °C for 1 min.
U6, U44 and U48 small RNAs, in different combinations,
were used as endogenous control. ΔΔCT method was used
for the calculation of expression ratios.
Pre-miR mimic transfection of glioma cells
In order to overexpress the down regulated miRNAs, the
precursors or mimics of corresponding miRNAs were
transfected into the glioma cell lines. The pre-miR mimics
and Cy-3- labelled Pre-miR control/unlabelled pre-miR
negative controls were obtained from Ambion. The trans-
fection of pre-miRs and their respective negative controls
involve a method called reverse transfection wherein the
transfection mix is added first to an empty dish and then
the dish is overlaid with the requisite volume of cell sus-
pension. The method involved the dilution of siPORT
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transfection reagent (Ambion) in a requisite volume of
OptiMEM medium (reduced serum medium) and this
mix was incubated at room temperature for 10 min.
Meanwhile the pre-miRs and their respective pre-miR-
negative controls (10 μM stock) were also diluted at a
particular concentration in OptiMEM. After 10 min of
incubation the diluted siPORT and the diluted pre-miR
were mixed together and again incubated at room
temperature for 10 more minutes. The mix was finally
added to an empty dish wherein the cell suspension
was overlaid subsequently at a desired cell density. The
dish was incubated in CO2 incubator. RNA was isolated
at the indicated time points and the overexpression of
miRNA was confirmed by assaying for the level of
mature miRNA by TaqMan quantitative real-time PCR
as explained before.
Colony suppression assay
Colony forming ability of cells upon miR overexpression
was gauged by initial transfection of negative control
pre-miR or pre-miR-326 in glioma cells. After 36 h of
transfection, cells were counted in each group and 2500
or 5000 cells were plated in a 12 well cluster plate. The
culture media was replaced every 3 days. After 2–3
weeks of plating, the colonies were fixed in chilled
methanol for 30 min and stained with 0.05 % crystal vio-
let for another 30 min and photographed.
Proliferation assay
Cells were transfected with negative control pre-miR or
pre-miRs for miR-326. After 24 h, cells were harvested
and plated (500 cells per well) in triplicates in a 96-well
cluster plate. Each day a triplicate set in each condition
was treated with MTT to quantify the number of viable
cells. 20 μl of MTT (5 mg/ml in PBS) was added to the
cells in 96-well plate. Three hours after MTT addition,
the formazan crystals were dissolved in DMSO (200 μl)
and measured as absorbance at 570 nm.
Wound healing scratch assay
Cells were initially transfected with negative control
pre-miR or pre-miR-326 and after 24 h of transfection
they were seeded in a 12 well cluster plate at a high
density. After 12–24 h, the monolayers were mechanically
disrupted with a sterile toothpick to produce a clean uni-
form scratch. The assay was performed in duplicates. The
wells were photographed every 12 h and the gap distances
were recorded at each time point to assess the closure of
the wound.
Western blotting
Western blotting was carried out to assay the changes in
protein expression or modification. Cells were washed
with chilled PBS and harvested by trypsinization. Cells
were lysed using RIPA (RadioImmunoPrecipitation Assay)
buffer. Requisite volume of RIPA buffer was added to the
cell pellet and the cell suspension was vigorously agitated
and vortexed and lastly incubated on ice for 30 min to
allow cell lysis. This was followed by centrifugation at
14,000 rpm for 15 min at 4 °C. The clear supernatant or
the protein lysate was collected in a fresh centrifuge tube
and stored at −20 °C. Protein lysates were quantified
by Bradford assay reagent (Bio-Rad) before subjecting
the same to immunoblotting. The protein were sepa-
rated on 10 or 12 % SDS-PAGE and then transferred
to PVDF (Polyvinylidene difluoride) membrane (Merck
Millipore). Samples belonging to a particular experi-
ment were run in a same gel under same experimental
conditions. The membrane was probed with the re-
quired antibody at a prescribed dilution overnight at
4 °C with gentle rocking. The antibodies that were
used in the study include: Phospho-Akt (Ser473) (Cell
Signalling technology; cat # 4060), Akt (Cell Signalling
technology; cat # 9272), α-Tubulin (Mouse mAb
(DM1A); cat # CP06).
miRNA microarray and data normalization
Total RNA (1 μg) from LY294002 treated and DMSO
control was labelled with Hy3 and Hy5 fluorescent
label, respectively, using the miRCURY LNA Array
power labelling kit (Exiqon, Denmark). The common
reference RNA was prepared by mixing equal quantity
of RNA from all the samples. The Hy3-labeled samples
and Hy5-labeled reference RNA sample were mixed
pair wise and hybridized to the miRCURY LNA™ micro-
RNA Array (6th Gen) (Exiqon). The array has capture
probes for all the microRNAs in human, mouse, rat and
their related viruses as annotated in miRBase Release v16.0.
The capture probes are Locked Nucleic Acid (LNA™)
enhanced oligonucleotides, complementary to mature
microRNAs. The experiment involves a competitive
hybridization of each sample with a reference pool. The
hybridization was performed using a Tecan HS4800
hybridization station (Tecan, Austria). The miRCURY
LNA Array microarray slides were scanned using the
G2565BA Microarray Scanner System (Agilent, USA)
and image analysis was performed using the ImaGene
7.0 software (BioDiscovery, USA). The quantified sig-
nals were background-corrected (Normexp with offset
value 10) and normalized using the global Lowess (LOcally
WEighted Scatterplot Smoothing) regression algorithm.
The median ratio of Hy3/Hy5 intensity for replicate
spots for each miRNA was obtained after normalization.
The values for Hy3/Hy5 ratio were log2-transformed. The
difference in log2 ratio for each miRNA (subtracting the
log2 ratio of a given sample from its respective control
sample) was considered in subsequent analyses.
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Transcriptome analysis by RNA sequencing
The RNA samples were assessed for quality and quantity
using Agilent’s Bioanalyser. 1 ug of RNA from each sample
was used for library preparation. Each sample was run in
duplicates to obtain the data. The library for sequencing was
prepared using TrueSeq RNA sample preparation kit as per
the manufacturer’s guidelines (Cat # RS-122- 2001). The
library was then re-quantified using Agilent’s Bioanalyser as
well as real-time qPCR. 120 ul (10pM) of each sample
library were taken, the strands were denatured and
finally subjected to cluster generation on the flow-cell
in the c-Bot system using TruSeq PE Cluster kit (Cat #
PE-401-3001). The flow cell was finally subjected to
two rounds of sequencing (Read1 and Read2) and the
results were obtained as intensity files. Sequencing was
conducted on Illumina HiScanSQ using Truseq SBS V3
technology for 50 base pair paired-end reads RNA se-
quencing (Cat # FC-401-3002). Raw reads obtained
were mapped to the human reference genome (hg19)
using TopHat (version 2.0.10). The alignment files were
thereafter subjected to Cufflink (version 2.2.0) to generate a
transcriptome assembly. Each of the transcriptome assem-
blies was merged using Cuffmerge utility, to generate the
final transcriptome assembly. The transcriptome assembly
thereby generated and alignment file were analysed through
Cuffquant utility to quantify gene and transcript expression.
Normalization of quantified gene and transcript expression
was carried out using Cuffnorm utility. Differentially
expressed genes were identified using Cuffdiff utility
and those having fold change above 1.5 with FDR-
adjusted p-value <0.05 were considered significant.
Transcription factor (TF) analysis
A 6 kb region in the promoter of ARRB1 that was marked
by significant enrichment of histone activation marks was
analysed for TF analysis. We used Matinspector, an online
transcription factor analysis tool to identify the putative
transcription factors that could potentially bind and regu-
late the expression of ARRB1 locus. The transcription
factors identified by Matinspector were further analysed for
their regulatory dependence on the PI3 kinase pathway. To
elucidate the transcription factors that were regulated by
PI3 kinase pathway, we analysed the expression of these
TFs in two sample cohorts characterised by high and low
phospho-Akt levels. Essentially, we divided the TCGA
GBM samples from the Reverse Phase Protein Array
(RPPA) into four quartiles based on their phospho-Akt
ser-473 levels (https://cancergenome.nih.gov/). The
samples that formed the two extreme quartiles were con-
sidered as high phospho-Akt samples (top 25 %, n = 49)
and low phospho-Akt samples (bottom 25 %, n = 49).
The differential expression of the TFs (output from
Matinspector) was finally compared only in these two
sample cohorts to assess their PI3 kinase dependent
regulation.
Histone landscape analysis
The histone marks across the ARRB1 locus were analysed
from the “Integrated Regulation from ENCODE Tracks”.
The landscape gave a picture of H3K4Me1 (found near
regulatory elements), H3K4Me3 (found near promoters)
and H3K27Ac (found near active regulatory elements). The
information about these histone marks was derived from 7
cell lines from ENCODE. It also provided the transcript




In order to compare and corroborate the expression of
miR-326 and other genes evaluated in the study, the fold
change was further derived from various publicly
available data portals, including The Cancer Genome
Atlas (TCGA) dataset (Agilent and Affymetrix platforms),
REMBRANDT dataset and GSE22867 dataset. TCGA
Agilent and Affymetrix data was accessed and downloaded
on 24/1/2013 (http://cancergenome.nih.gov/). The REM-
BRANDT data was accessed and downloaded on 17/2/
2011 (ftp://caftpd.nci.nih.gov/pub/caARRAY/experiments/
caArray_fine-00037/). GSE22866 data was accessed and
downloaded on 08/07/2013.
Bioinformatic analysis
Gene targets for miR-326 were predicted using miRWalk
(http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/),
an online target prediction tool which provides results
compiled from 12 algorithms.
Gene ontology and pathway analysis
Gene ontology mining and pathway analysis was carried
out using DAVID (https://david.ncifcrf.gov/) Bioinfor-
matics Resources tool.
Statistical analysis
Statistical significance between two groups was calcu-
lated by unpaired student’s t-test using the GraphPad
PRISM software. In experiments involving more than
one group for comparison, ANOVA was used with a
suitable post-hoc test. In the correlation study, we used
spearman correlation method to calculate the correlation
coefficient. The statistical significance is indicated as
asterisks (*). P < 0.05 was considered to be statistically
significant, (ns) not significant; (*) p ≤ 0.05; (**) p ≤ 0.01
and (***) p ≤ 0.001.
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Results
miRNAs regulated by PI3 Kinase pathway
PI3 kinase pathway is one of the most genetically
altered pathways in glioblastoma and thereby potentiates
the aberrant expression of a number of oncogenes and
tumour suppressor genes downstream to it. With an object-
ive to identify the miRNAs regulated by the activated PI3
kinase pathway in GBM, we examined the expression of
miRNAs after abrogating the pathway in U87 and U251
glioma cell lines. Cells were treated with LY294002, a
selective, potent inhibitor of PI3 kinase which essen-
tially inhibits the activity of phosphatidylinositol-4,5-
bisphosphate 3-kinase and thereby the synthesis of
phosphatidylinositol (3,4,5)-trisphosphate. This inhibition
eventually blocks the phosphorylation of Akt (PKB) and the
subsequent signaling. We probed the activity of PI3 kinase
inhibition after LY294002 treatment by reading out the
phosphorylation status of its target protein Akt through
western blot analysis. We demonstrated that LY294002
inhibited the PI3 kinase pathway as early as 30 min, as the
levels of phospho- Akt were significantly reduced at least
till two hours of treatment in U87 cell line. In U251 cell
line, the phosphorylation of Akt was lost at 60 min of treat-
ment but continued to remain less till two hours of examin-
ation (Fig. 1a and b).
To unveil the miRNAs regulated by the PI3 kinase
pathway, we isolated RNA after 24 h of LY294002 treat-
ment from the two different glioma cell lines: U87 and
U25, and subjected it to miRNA micro-array using
miRCURY LNA™ microRNA Array (6th Gen) platform
developed by Exiqon Inc. We observed a large number
of miRNAs being differentially expressed upon PI3 kin-
ase pathway inhibition in both U87 and U251 cell lines
as indicated in the volcano plot (Fig. 1c). There were 22
upregulated miRNAs and 25 downregulated miRNAs
that were significantly different between the untreated
and LY294002 treatment condition (Additional file 1:
Table S1). The differential regulation of these miRNAs
in each of the cell lines (U87 and U251) is shown in the
form of a heat map (Fig. 1d). By applying an additional
cut-off of +/− 0.57 fold change (Log2 scale), we were
able to narrow down to 16 unique miRNAs that were
commonly and similarly regulated in U87 and U251
cells (Additional file 2: Table S2). Next, we investigated
the expression of these miRNA in GBM tumour samples.
We hypothesized that if a miRNA gets upregulated upon
LY294004 treatment, it must be downregulated in GBM
and vice versa. From this analysis, we inferred that if a par-
ticular miRNA is repressed in GBM by an activated PI3
kinase pathway, the inhibition of pathway would result in
alleviating the levels of that miRNA, resulting in its upregu-
lation. Thus, we relied upon the differing expression of
miRNAs between LY294002 treated cells and their expres-
sion in GBM (Additional file 2: Table S2). Based on the
limited miRNA expression data available, we were able to
identify three miRNAs: miR-326, miR483-5p and miRPlus-
C1115 which were downregulated in GBM but the inhib-
ition of the PI3 kinase pathway alleviated their transcript
levels (Additional file 2: Table S2).
miR-326 is downregulated by the PI3 kinase activity
From the microarray data, we found that miR-326 was
one of the upregulated miRNAs upon PI3 kinase pathway
inhibition in both U87 and U251 cell lines (Fig. 2a). We fur-
ther validated our array results by quantitative PCR, which
revealed the upregulation of miR-326 upon LY294002 treat-
ment at two different time points in U87 and U251 cell
lines by qRT-PCR (Fig. 2b and c). Being upregulated upon
inhibition of the PI3 kinase pathway, we expected miR-326
to be downregulated in GBM. In fact, we observed that
miR-326 was significantly downregulated in GBM com-
pared to control brain in the TCGA data set as well as in
our lab microarray dataset (Fig. 2d and e) (Additional file 3:
Table S3a, b). We also assayed the levels of miR-326 in an
independent sample cohort using qRT-PCR and demon-
strated that indeed miR-326 was a down-regulated miRNA
in GBM (Fig. 2f) (Additional file 3: Table S3c). As expected
the expression levels of miR-326 were also significantly low
in most of the glioma cell lines we examined - SVG, IHA,
LN18, U373, T98G, LN229, U343, U138, U251 and U87
(Fig. 2g). Thus from our results, we conclude that miR-326
is a downregulated miRNA in GBM and its low expression
is brought about by aberrant PI3 kinase signaling.
miR-326 over-expression exerts tumour suppressive effects
in glioblastoma
Since miR-326 is downregulated by the activated PI3
kinase pathway and is lowly expressed in GBM, we over-
expressed it by pre-miR-326 transfection in LN229 cell
line and studied its effect on various parameters related
to cancer phenotype. The pre-miR-326 transfection in-
deed resulted in high levels of mature miR-326 in LN229
cells (Fig. 3a). We observed that the re-expression of miR-
326 induced significant reduction in colony forming ability
of glioma cells as well as inhibited the rate of proliferation
(Fig. 3b, c and d). In addition to that miR-326 over-
expression also retarded the migration of cells to fill the
gap, mimicking a wound (Fig. 3e and f). These data indi-
cate that miR-326 being down-regulated in GBM has
tumour suppressive effects as it imparts colony suppres-
sion and inhibits the proliferation of cells as well as their
migratory potential.
ARRB1, the host gene of miR-326 is also regulated by PI3
Kinase pathway
miR-326 is an intragenic miRNA and is located in the
first intron of the gene Arrestin Beta-1 (ARRB1) (Fig. 4a).
Since miR-326 was regulated by the PI3 kinase pathway,
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we hypothesized whether its host gene, ARRB1 is also
subjected to PI3 kinase signaling mediated regulation.
We initially analysed the transcript levels of ARRB1 in
GBM across different publicly available data sets and
observed that it was significantly down-regulated in
GBM as well as in the lower grades (Fig. 4b and c)
(Additional file 3: Table S3d, e, f, g). Further, to deter-
mine whether ARRB1 was regulated by the PI3 kinase
pathway, we measured its expression upon PI3 kinase
inhibition in two cell lines: LN229 and U87. We ob-
served that indeed like miR-326, the transcript level of
ARRB1 was also getting alleviated, indicating that
ARRB1 was also negatively regulated by the PI3 kinase
signalling pathway (Fig. 4d). This observation led us to
the assumption that possibly miR-326 and ARRB1 are
under the control of a common promoter upstream to
ARRB1 locus. Next, to substantiate our assumption, we
analysed the expression of ARRB1 and miR-326 in an
identical sample set to figure out if there exists any
close relation in terms of expression, between the two.
We used ARRB1 transcript levels from two different
platforms (Affymetrix and Agilent) of the TCGA data-
set and correlated them with miR-326 expression in an
identical sample cohort. We found that there exists a
significant positive correlation between miR-326 and
ARRB1 transcripts in GBM (Fig. 4e and f ). However,
the correlation coefficient was not so high, which
suggested the possibility that ARRB1 and miR-326 tran-
scripts might have differing relative stabilities and half-
lives. In addition, it is also possible that miR-326 may
be transcribed from its own independent promoter. In
order to investigate this possibility, we analysed the
read counts corresponding to various introns and exons
of the ARRB1 gene derived from the RNA sequencing
data from TCGA. Assuming that ARRB1 and miR-326 are
transcribed from independent promoters, we expected to
observe higher number of transcript reads corresponding
to intron-1 as against the remaining introns of the ARRB1
gene. On the contrary, we observed that the normalized
read count of the region corresponding to intron-1 was
no different from the remaining introns of ARRB1 gene in
control brain and GBM tissue samples (Additional file 4:
Figure S1a, b), strongly suggesting that this intron did not
give rise to any primary miRNA corresponding to miR-
326 independently. Moreover, the normalised read count
of the intron-1 was significantly less than that of exon-1,
further consolidating our hypothesis that miR-326 tran-
script was not synthesized independent of its host gene
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Fig. 1 PI3 kinase pathway regulated miRNAs in glioblastoma a, b. Western blot data indicating the time course loss of phosphorylation of AKT
upon PI3 kinase inhibition by LY294002 (50 μM) treatment in two different cell lines U87, and U251 respectively. Also indicated is the densitometric
quantification of p-AKT/AKT levels at different time points. The first bar of each plot represents the untreated (UT) condition, where equal volume of
DMSO was added as vehicle control. The quantitation and the statistics in the column plots has been deduced from three independent experiments.
p values were calculated by student’s t-test and the symbols are indicated. (**) p≤ 0.01; (***) p≤ 0.001. c. Volcano plot representing the significantly
regulated miRNAs upon LY294002 treatment, 15 miRNAs (indicated by red dots) were found to be upregulated upon PI3 kinase pathway inhibition
and 1 (indicated by green dots) miRNA was upregulated. miRNAs were considered significant based on their p value and differential Log2 ratio (more
than +/− 0.57 fold). d. Heat map of the 47 miRNAs derived from the volcano plot which were significantly different upon LY294002 treatment in U87
and U251 cell lines
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ARRB1. Additionally, we also evaluated the active his-
tone marks across the ARRB1 locus using “Integrated
regulation from ENCODE tracks”. While only one of
the histone mark H3K4Me1 which is essentially suggest-
ive of enhancer region, was enriched in the intronic region
upstream to miR-326 locus, all the three marks
H3K4Me1, H3K4Me3 and H3K27Ac were enriched in the
ARRB1 promoter region (Additional file 4: Figure S1c).
Importantly, the enrichment of H3K4Me3 mark was
worth noticing in the region upstream to ARRB1, as this
histone mark is characteristic of promoters. This data pro-
vides yet another evidence that the PI3 kinase pathway es-
sentially regulates ARRB1 promoter, thereby modulating
the expression of miR-326 as well as ARRB1.
Next, to ascertain the mechanism through which PI3 kin-
ase pathway brought about this regulation, we examined the
transcription factors that could putatively bind to the
promoter region of ARRB1 (see Methods for detail). A
segment of 6 Kb in length in the region covering the active
histone activation marks towards the 5’ end of ARRB1 was
analysed for transcription factor binding using Matinspector,
an online transcription factor analysis tool. Since ARRB1
and miR-326 are co-regulated by the PI3 kinase pathway,
we expected the transcription factors controlling their ex-
pression also to be regulated by the PI3 kinase pathway. We
divided the samples from the TCGA Reverse Phase Protein
Array (RPPA) data between high and low phospho-Akt
groups to identify the differentially regulated transcription
factors. A list of 1831 transcription factor (TF) entries ob-
tained from Matinspector TF analysis, were assayed for their
expression levels in GBM between high and low activated
Akt TCGA samples (Additional file 4: Figure S2). We ob-
tained 48 TF entries that had significantly different expres-
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Fig. 2 miR-326 is a PI3 kinase regulated miRNA and is downregulated in glioblastoma. a. Transcript levels of miR-326 in U87 and U251 cells upon
24 h of LY294002 treatment in the miRNA-microarray. b, c. Transcript levels of miR-326 in U87 and U251 cells upon PI3 kinase pathway inhibition
by LY294002 treatment (50 μM). The transcript levels were assayed at 12 and 24 h time points by real time quantitative PCR. d, Scatter plot depicting
the downregulation of miR-326 in GBM in the TCGA dataset as compared to control brain samples. e, Scatter plot depicting the downregulation of
miR-326 in GBM in the lab dataset (microarray), each dot represents one sample and for each tumour sample fold change is calculated as difference in
the expression value of the miRNA over the average of its expression values in the control brain samples. f, Scatter plot depicting the Log2 transformed
miR-326 expression values obtained from qRT-PCR analysis in an independent cohort of GBM samples as compared to control brain samples. g, Log2
transformed miR-326 expression values obtained from qRT-PCR analysis in GBM cell lines LN18, U373, T98G, LN229, U343, SVG, IHA, U138, U251 and
U87. For each GBM sample or cell line, fold change in miRNA expression is calculated over its mean expression in control brain samples. p values were
calculated by student’s t-test and the symbols are indicated. (*) p≤ 0.05; (**) p≤ 0.01; (***) p≤ 0.001
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22 TF entries had more expression in low Akt GBM sam-
ples which could potentially be the transcriptional activators
of ARRB1 and are suppressed by the PI3 kinase pathway
(Additional file 4: Figure S2). We also obtained 26 TF entries
that had more expression in high Akt GBM samples
which could potentially be transcriptional repressors of
ARRB1 and are activated by the PI3 kinase pathway
(Additional file 4: Figure S2). To further narrow down
on the potential transcription factors that regulated
ARRB1 locus, we chose those TFs that had a binding
site on the negative DNA strand as both miR-326 and
ARRB1 reside on the negative strand (Additional file 5:
Table S4). We shortlisted 4 unique potential transcriptional
activators and 7 potential transcriptional repressors, as
many of the TF entries had more than one binding site and
finally subjected them to correlation analysis with
ARRB1 transcript levels (Additional file 4: Figure S2).
Out of 4 transcription activators, Zic family member 3
(ZIC3) alone significantly and positively correlated with
ARRB1 expression (Table 1), while as out of 7 transcrip-
tion repressors SRY-box 6 (SOX6), INSM transcrip-
tional repressor 1 (INSM1) and zinc finger protein 300
(ZNF300) significantly and negatively correlated with
ARRB1 expression (Table 1). Thus, it appears PI3 kin-
ase regulates these transcription factors ZIC3, SOX6,
INSM1 and ZNF300 which eventually results in the
downregulation of ARRB1 and miR-326 in GBM.
miR-326 regulated genes demonstrate its role in
gliomagenesis
In order to find the putative downstream targets (both
direct and indirect) of miR-326 in GBM, we overex-
pressed miR-326 by pre-miR transfection and carried
out the transcriptome analysis by RNA sequencing at
two different time points (48 and 72 h) in LN229 cell
line. We observed a multitude of genes getting regu-
lated after miR-326 overexpression at both time points
as depicted through the volcano plots (Fig. 5a and b).
We shortlisted the genes regulated by miR-326 based
on their fold change and p-value significance. We found
143 genes to be upregulated and 333 genes to be downreg-
ulated upon pre-miR-326 transfection at the 48 h time
point and 114 genes to be upregulated and 64 genes to be
downregulated at the 72 h time point (Additional file 6:
Tables S5 and Additional file 7: Table S6). In order to































































































Fig. 3 miR-326 over-expression exerts tumour suppressive effects in glioblastoma. a. Log2 transformed miR-326 expression value obtained from
qRT-PCR analysis upon its over-expression in LN229 cell line. b, c. LN229 cells were transfected with Pre-miR-neg or Pre-miR-326, cells were
counted and indicated numbers of cells (a = 3000 and b = 6000 cells) were plated in duplicates in a 12-well cluster plate. After 3 weeks of plating,
the colonies were stained with crystal violet, photographed (b) and counted (c). % colony density and ± Sd is plotted. d. LN229 cells transfected
with Pre-miR-neg or Pre-miR-326 were subjected to proliferation assay. Proliferation was assessed by MTT assay, measuring OD (570 nm) for both
miR-neg and miR-326 at each time point. For each condition and time point, the samples were plated in triplicates and the standard deviation
was calculated over three independent biological replicates. Significance is indicated for different time points. e, f. LN229 cells transfected with
Pre-miR-neg or Pre-miR-326 were subjected to scratch assay (e), migratory potential of cells was quantitated by the percent of wound remaining
after the indicated time point (f). p values were calculated by student’s t-test using graph pad prism and the symbols are indicated. (*) p≤ 0.05;
(**) p≤ 0.01; (***) p≤ 0.001
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downregulated genes obtained through RNA sequencing,
we employed an integrated bioinformatics approach as
explained in the schematic (Fig. 5c). A separate analysis of
the data from two time points (48 and 72 h) revealed a
set of genes that were significantly downregulated (cut-
off −0.57 and less in the Log2 scale), in either of the
time points. We shortlisted the downregulated genes
exclusively, as only they could serve as the putative
targets of miR-326 (Fig. 5c). Simultaneously, we also
extracted the in silico gene targets of miR-326 using
miRWalk 2.0, an online utility which is a cumulative
web-tool of 12 prediction algorithms (Fig. 5c). The
intersect of genes predicted in silico and the ones
downregulated by mir-326 overexpression were taken
for further study. The genes were finally shortlisted
based on their expression in GBM as compared to con-
trol brain. We observed 62 genes to be significantly up-
regulated in GBM, which satisfied our hypothesis that
the genes whose transcript levels were brought down
by miR-326, need to be upregulated in GBM in order
make a physiological relevance. To further authenticate
these genes as the potential targets of miR-326, we
carried out a correlation study between their transcript
levels and miR-326 expression. We obtained a list of 29
genes that exhibited a significant negative correlation
with the miR-326 expression (Fig. 5c) (Additional file 8:
Table S7). The list of genes represents the putative tar-
gets miR-326. In order to ascribe functional relevance
to our gene list of putative miR-326 targets, we carried
out an unbiased functional enrichment analysis of this
list of 29 genes. The gene ontology and pathway analysis
using DAVID unveiled the functional role of miR-326 in
gliomagenesis as it depicted a significant enrichment of
various terms and pathways related to cell migration like
focal adhesion, extracellular matrix-receptor interaction, in-
tegrin signalling pathway, cell adhesion mediated signalling,
regulation of cell motion (Fig. 6). All these terms essentially
explain the phenotype that we observed with miR-326 over-
expression in GBM.
We further validated some of the genes from the putative
target gene list which include COL4A1, NOB1, PPIC, and
ITGB8 (Fig. 7a). We also analysed the transcript levels of
these genes across other different publicly available datasets
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5’ UTR 3’ UTR
Fig. 4 Arrestin beta 1, the host gene of miR-326 is also regulated by PI3 kinase pathway and is downregulated in GBM. a. Schematic representation of
the genomic locus of MIR326 gene in the intronic region of ARRB1 gene. MIR326 resides in the first intron of ARRB1. b, c. Log2 transformed ARRB1
expression values obtained from different publicly available expression data sets, TCGA i (Affymetrix), TCGA ii (Agilent), GSE22866 and REMBRANDT data
set respectively. Each dot represents one sample and for each sample fold change in expression is calculated over its mean expression in control brain
samples. p values were calculated by student’s t-test or ANOVA (c) and the symbols are indicated. (*) p≤ 0.05; (***) p≤ 0.001. d, e. Correlation graph
between hsa-miR-326 and ARRB1 transcripts using two different expression platforms from TCGA agilent (d) and affymetrix (e). ARRB1 and miR-326
exhibit a significant positive correlation in their abundance with a correlation coefficient R = 0.2446 and p < 0.0001 (agilent) and R = 0.2137 and
p < 0.0001 (Affymetrix). f. Log2 transformed expression values of ARRB1 upon PI3 kinase pathway inhibition with LY294002 treatment (50 μM)
in two different cell lines LN229 and U87 for two time points (6, 12 h)
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were significantly upregulated in GBM, underscoring the
importance of these genes to be the putative targets of
miR-326 (Fig. 7b).
Discussion
miRNAs indeed play a decisive role in tumourigenesis as
their misregulation leads to the aberrant expression of
their target genes which happen to function as oncogenes
or tumour suppressors [21, 22]. In addition to the alter-
ations in the protein coding genes, GBM transcriptome
also presents an altered picture of the miRNome [23, 24].
miRNAs can certainly function as oncogenes and tumour
suppressors in GBM as well, as has been reported in many
studies. There are umpteen studies that have depicted the
Table 1 PI3 kinase regulated transcription factors that can impact the expression of ARRB1 genetic locus
S.No Gene Log2 FC p-Akt high vs low No of binding sites Regulation in GBM Log2 fold change Correlation with ARRB1 (R) p-value
1 ZIC3 −0.53 6 −0.35 (Down) +0.085 0.0408
3 SOX6 0.50 4 0.57 (Up) −0.125 0.0025
4 INSM1 0.50 2 0.69 (Up) −0.141 0.0006



























Fig. 5 Transcriptome analysis upon miR-326 overexpression. a, b. Volcano plot representation of the RNA sequencing data, indicating the genes
significantly and differentially expressed between Pre-miR-neg and Pre-miR-326 condition in LN229 cell line at two 48 h and 72 h time points
respectively. Each red dot indicates a gene significantly upregulated in Pre-miR-326 overexpression condition and each green dot indicates a
gene significantly downregulated in Pre-miR-326 overexpression condition. The figures (bolded) inside each plot denote the number of genes
upregulated and downregulated significantly, Green indicates the downregulated genes and red indicates the upregulated genes. c. Schematic
representation of miRNA target prediction. All the genes downregulated (−0.57 and less in the Log2 scale) upon miR-326 overexpression from
both 48 and 72 h time point were sought for the analysis. miR-326 targets were derived from 12 target prediction algorithms (miRWalk, MicroT4,
miRanda, miRBridge, miRDB, miRMap, miRNAMap, PICTAR2, PITA, RNA22, RNAhybrid, Targetscan) assembled in miRWalk 2.0 online tool. The
experimental targets were compared with the in silico targets to find out the common ones, which were finally compared for their expression in
GBM and their correlation with miR-326 expression
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deregulation of miRNAs in GBM, which in addition to
displaying the distorted landscape of miRNome have also
proven useful in terms of diagnosis as well as prognosis
[25, 26]. Variations in the expression of miRNAs have
been associated with almost every facet of tumour biology
like, cell proliferation, migration, angiogenesis and chemo-
resistance [7, 22].
There is a multitude of ways by which the abundance
of miRNAs can get affected. One of the most important
and plausible mechanisms that affects the expression of
miRNAs, is through transcriptional control. With the
aim to elucidate the changes in the miRNome governed
by the PI3 kinase pathway, we observed that the abrogation
of the PI3 kinase pathway resulted in the alteration of the
miRNome of the glioma cells. We identified a set of
miRNAs whose expression was elevated upon PI3 kinase
pathway inhibition, as well as a cohort of miRNAs whose
transcript levels were brought down upon PI3 kinase
pathway inhibition. Based upon the concurrence we ob-
tained from their expression values in GBM, we identified
miR-326 as one of the PI3 kinase pathway regulated
miRNA. Thus, miR-326 is downregulated in GBM owing
to the aberrant activity of the PI3 kinase pathway. The
downregulation of miR-326 has also been reported previ-
ously in few other studies [27, 28]. Ectopic expression of
miRNA-326 in glioma and glioma stem cells resulted in
the induction of apoptosis and also declined the metabolic
activity of the malignant cells [27]. miR-326 has also been
shown to effect the viability and invasiveness of glioma
cells [29]. In yet another study, miR-326 was identified to
regulate stemness by targeting SMO gene, which is an im-
portant component of the hedgehog signaling. SMO is up-
regulated in gliomas and is associated with tumour grade
and has prognostic implications as well [30]. miR-326 was
also demonstrated as an inhibitor of the Notch pathway
and it in turn was also inhibited by Notch [27]. In addition
to that, PKM2 was validated as the direct target of miR-
326, thereby explaing the metabolic decline in the cells
which overexpressed miR-326 [29]. miR-326 along with
two other miRNAs (miR-125b and miR-324-5p) were
found to regulate the downstream targets of the hedgehog
signalling, in particular of Smo and Gli1 [31]. In concur-
rence with the above observations and reports, we also
observed that the reintroduction of miR-326 resulted in
a growth suppressive phenotype, affecting the prolifera-
tion and migration of glioma cells, thereby indicating
that the downregulation of miR-326 by the aberrant PI3
kinase signaling is an important event in the course of
gliomagenesis.
In our study, we identified a set of genes which could
be the potential targets of miR-326, as they were tran-
scriptionally repressed by miR-326 and many of them
happened to be upregulated in GBM as compared to
control brain. The gene ontology and pathway analysis
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Fig. 6 Gene ontology analysis of the putative targets of miR-326. a, b. DAVID based gene ontology analysis (a) and pathway analysis (b) of the 29
putative targets of miR-326 indicates significant enrichment of the cell migration and invasion related terms and pathways
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of these putative targets of miR-326 revealed a signifi-
cant enrichment of various terms relevant to migration
and invasive phenotype. In fact, we identified a signifi-
cant enrichment in the integrin signalling, which points
to the role of miR-326 in modulating integrin mediated
signalling to compromise the migratory phenotype.
Some of the putative targets that we narrowed upon like
Notch2 and NOB1 have already been proven to be the
targets of miR-326 [27, 28]. Among the other targets we
demonstrated that miR-326 indeed resulted in the down-
regulation of COL4A1, NOB, PPIC and ITGB8, possibly
explaining the phenotype affected by miR-326 re-
expression as these genes can directly affect the pro-
cesses like cell migration and invasion. COL4A1 encodes
a type IV collagen alpha protein and interact with the
components of the basement membrane like perlecans,
proteoglycans, and laminins. The alteration and further
mutilation of the extracellular matrix can definitely have
oncogenic propensity. ITGB8, which encodes a protein
of integrin beta chain family, mediates cell-cell and cell-
extracellular matrix interactions, thereby modulating the
extra cellular milieu in favour of tumorigenesis [32].
Thus, in addition to influencing the hedgehog and notch
signalling as reported previously, miR-326 can poten-
tially modulate integrin signalling in the course of
gliomagenesis.
miR-326 is an intragenic miRNA, possibly a mirtron
as its genetic locus is in the first intron of its host gene
Arrestin β1 (ARRB1). Both the miRNA and its host genes
are located on the same strand (negative) thereby having
same orientation. As reported previously, the levels of
ARRB1 are also downregulated in glioblastoma [27].
Moreover, we also observed a significant correlation in
the expression of miR-326 and ARRB1, possibly suggesting
that miR-326 expression was governed by the transcrip-
tional control of ARRB1. This was further corroborated by
the fact that the transcript levels of ARRB1 increased upon
the inhibition of the PI3 kinase pathway. Our transcription
factor analysis revealed various crucial transcription factors
like SOX6, INSM1, ZNF300 and ZIC3 to be differentially
regulated by the PI3 kinase signaling. These transcription














































































































































Fig. 7 Validation of the putative miR-326 targets. a. The column plot depicts the putative targets of miR-326 since they were downregulated
upon Pre-miR-4484 transfection, validated through qRT-PCR analysis. b. Transcript analysis of the genes downregulated upon miR-326 overexpression.
Data derived from TCGA and GSE22866 datasets. TCGA i and TCGA ii refer to Affymetrix and Agilent platform respectively. p values were calculated by
student’s t-test and the symbols are indicated. (ns) not significant; (**) p≤ 0.01 and (***) p≤ 0.001
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ARRB1 indicating a possible dependence for its expres-
sion. SOX6, INSM1 and ZNF300 were expressed more
in the high phospho Akt GBM samples and exhibited a
significant negative correlation with ARRB1, thereby in-
dicating that these could function as the potential tran-
scriptional repressors of ARRB1 (Table 1). ZNF300 is a
zinc finger protein, expressed mostly in heart, skeletal
muscle and brain and exhibits transcription repressor
activity [33]. ZNF300 promoter activity was found to be
regulated by PU.1 transcription factor in acute promye-
locytic leukemia [34]. In yet another report, it was ob-
served that Akt induces the transcriptional activity of
PU.1 by modifying it post-translationally through phos-
phorylation [35]. This hints to the possibility that PI3
kinase pathway can potentially activate ZNF300, which
thereby mediates the repression of ARRB1 locus. More-
over, we also observed that, ZNF300 was upregulated in
GBM compared to control brain (Table 1). INSM1, yet
another zinc-finger transcription factor that could po-
tentially repress ARRB1 locus was also upregulated in
GBM compared to control brain (Table 1). It is exclu-
sively expressed in the nervous system and foetal pan-
creas and functions as transcription repressor in a
Cyclin D1 and HDAC dependent fashion [36]. SOX6
was found to specifically expressed either in foetal brain
or gliomas, but faintly in the adult brain [37, 38], which
again indicates that it might have a role in transform-
ation by repressing various tumour-suppressive targets
like the ARRB1 locus. SOX6 was also upregulated in
GBM compared to control brain (Table 1). In contrast,
ZIC3 was more expressed in the low phospho-Akt GBM
samples and exhibited a significant positive correlation
with ARRB1 and thus may function as the potential tran-
scriptional activator of ARRB1 (Table 1). The expression
of ZIC3 was significantly downregulated in GBM as well,
hinting to its function as a positive regulator of ARRB1
(Table 1). Briefly, we identify four transcription factors
ZNF300, INSM1, SOX6 and ZIC3 that are regulated by
PI3 kinase signalling and can impact the expression of
ARRB1-miR-326 locus. Additionally, a study has previ-
ously verified that the levels of miR-326 increased when
the Notch signalling was abrogated, and there being vari-
ous reports which furnish substantial evidences of cross-
talk between Notch and PI3 kinase [39–41], we speculate
that PI3 kinase pathway, by altering the Notch signalling
or vice versa, can also result in the transcriptional silen-
cing of the miR-326 locus.
Conclusions
In summary, our study indicates that the PI3 kinase
pathway indeed modulates the expression of miRNAs in
a pro-oncogenic manner. We identify various miRNAs
whose levels are altered upon silencing of the PI3 kinase
pathway. Many of these miRNAs are inversely regulated
in glioblastoma. We report here the first evidence that
the expression of miR-326 is inhibited by the aberrant
PI3 kinase signalling thereby resulting in its downregulation
in GBM. In fact, the hyperactivity of PI3 kinase pathway
results in the downregulation of an array of tumour sup-
pressor genes and our finding appends this list by one more
gene: miR-326. Additionally, miR-326 is significantly down-
regulated in GBM samples and its reincorporation exhib-
ited tumour suppressive effects.
miR-326 portrays a strong correlation in its expression
with its host gene, ARRB1. Later, we even demonstrated
that ARRB1 expression is also suppressed by PI3 kinase
pathway and is downregulated in GBM as well, suggesting
that miR-326 expression is controlled by its host gene
regulation which in turn is governed by the PI3 kinase
pathway. Our in silico analysis of the promoter region of
ARRB1 also identifies some of the potential transcription
factors which are regulated by PI3 kinase signalling in
GBM and can alter the transcription profile of the ARRB1
locus, there regulating miR-326 expression as well.
Additionally, we identify various putative targets of
miR-326 that are downregulated upon miR-326 overex-
pression and are also predicted through bioinformatics
analysis. Most of these genes are upregulated in GBM and
negatively correlate with miR-326 in terms of their abun-
dance, indicating that miR-326 could be mediating its
tumour suppressive function by targeting these genes.
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